Abstract from Interim Report Q2-2009

ABSTRACT FROM INTERIM REPORT JANUARY-JUNE, Q2-2009

Read the full Abstract.

SECOND QUARTER
-
Net sales SKr 34.1 (25.3) million – increased 35 %
- EBITDA SKR 1.0 (-3.5) million – improved with SKr 4.5 million
- Earnings before tax SKr -0.4 (2.3) million
- Net earnings SKr -0.3 (2.3) million
- Earnings per share SKr -0.02 (0.11)

FIRST HALF / YEAR-TO-DATE
- Net sales SKr 60.7 (48.7) million – increased 25 %
- EBITDA SKr 3.3 (-4.4) million – improved with SKr 7,7 million
- Earnings before tax SKr 0,9 (0,2) million
- Net earnings SKr 22,9 (16,2) million*
- Earnings per share SKr 1,14 (0,81)

(* including deferred income tax SKr 22.0 (16.0) million)

BUSINESS PROGRESS
- Continued positive market development

- Strong increase in net sales

- Important reference orders

- Good market reception for launched products

- Further improved earnings – EBITDA margin 9.2 % on annual basis

- Consolidation of sales organization and distribution partner network

- Name change to Biolin Scientific done

CEO COMMENT

”Sales development during Q2 was better than expected. We also managed to generate positive earnings. Our prospects are continuously improved through increased levels of research grants, which is expected to lead to a further improved market situation towards the end of 2009 and in 2010.” says Fredrik Lindgren, CEO of Biolin Scientific.